Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.98 |
| ▸ | TP53 | P04637 | 3/20 | 0.98 |
| ▸ | FLT3 | P36888 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | CNR2 | P34972 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
| ▸ | CASP7 | P55210 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20704641 | 0.89 | MAPT (0.79) | MAPTTP53FLT3MEN1RECQL | |
| SCHEMBL8290405 | 0.86 | FLT3 (1.00) | MAPTTP53FLT3MEN1RECQL | |
| SCHEMBL29766887 | 0.86 | FLT3 (1.00) | MAPTTP53FLT3MEN1RECQL | |
| SCHEMBL22095967 | 0.85 | FLT3 (1.00) | MAPTTP53FLT3MEN1RECQL | |
| SCHEMBL7892222 | 0.85 | MAPT (0.84) | MAPTTP53CNR2KDM4EALDH1A1 | |
| SCHEMBL20704522 | 0.85 | FLT3 (0.73) | MAPTTP53FLT3CNR2POLB | |
| SCHEMBL24425732 | 0.84 | FLT3 (1.00) | MAPTTP53FLT3MEN1RECQL | |
| SCHEMBL3914054 | 0.84 | MAPT (0.82) | MAPTTP53FLT3MEN1KMT2A | |
| SCHEMBL30148150 | 0.84 | FLT3 (1.00) | MAPTTP53FLT3MEN1RECQL | |
| SCHEMBL3917114 | 0.84 | MAPT (0.82) | MAPTTP53FLT3CNR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PATO JANOS | 2009-12-03 | — | — | US | claimed |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | AXXIMA PHARMACEUTICALS AG (DE) | 2009-01-15 | — | — | US | claimed |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | VICHEM CHEMIE KFT (HU) | 2004-09-02 | — | — | US | claimed |
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PATO JANOS | 2009-12-03 | — | — | US | disclosed |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | AXXIMA PHARMACEUTICALS AG (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-1492783-A1 | 4,5,6,7-TRETRAHYDROBENZO(B) THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS | Axxima Pharmaceuticals AG (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | VICHEM CHEMIE KFT (HU) | 2004-09-02 | — | — | US | disclosed |
| WO-2003084947-A1 | 4,5,6,7-TRETRAHYDROBENZO[B] THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PKLR, MASTL, BPGM | MAPT 3062/4885TP53 1772/4885FLT3 1858/4885 |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PKLR, PKN1, PKMYT1 | MAPT 2046/4885TP53 1999/4885FLT3 1906/4885 |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | STK4, SBK3, STK17B | MAPT 2119/4885TP53 563/4885FLT3 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.